Merck & Co., Inc. (NYSE: MRK) operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
- Market Cap: 292.621 Billion
- PE Ratio: 20.19
- EPS: 5.71
- Dividend Yield: 2.53%
Merck is a pharmaceutical powerhouse. Merck’s trailing 12-month free cash flow is $15.2 billion. Based on a market cap of $272.6 billion, it has a free cash flow yield of 5.6%. I consider anything between 4% and 8% to be fair value. Up nearly 40% on the year, it looks ready to finish the year on a high note. Therefore, Merck is a top DOW stock to own for long term.